{"ticker": {"uuid": "93342f83-fc9d-4098-bc4a-a628853dae73", "symbol": "ACIU", "name": "AC Immune Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC\u00ae 2026", "summary": "AC Immune SA announced it will present three times at the Alzheimer's Association International Conference\u00ae 2026, highlighting its Morphomer\u00ae-based small molecule approach for neurodegenerative diseases. The presentations will cover encouraging early human imaging data for a TDP-", "url": "https://finance.yahoo.com/healthcare/articles/ac-immune-showcase-neurodegenerative-disease-110000523.html", "source_name": "Market source", "published_at": "2026-07-08T13:14:12", "published_display": "08 Jul 2026 13:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune brings three neurodegeneration studies to AAIC 2026", "summary": "AC Immune (NASDAQ: ACIU) will present three pipeline studies at the Alzheimer's Association International Conference (AAIC) 2026, taking place from July 12-15 in London, UK. The presentations will cover a first-in-class TDP-43 PET tracer, a brain-penetrant NLRP3 inhibitor, and an", "url": "https://www.stocktitan.net/news/ACIU/ac-immune-to-showcase-neurodegenerative-disease-pipeline-with-three-663ci5zw1j5a.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:10:06", "published_display": "07 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune: Holding Into A Make-Or-Break H2 2026 Readout (NASDAQ:ACIU)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOc0loMmtzVXRJeFItM0FNWUpyRkJibnFsX040MlBuMkxleUpKSjh4QThPVGhSdHZ2VDVlVVo4elRNR0s0bkZzdld1dzY0bVFOcS1uOUdiZGFUeUJDTzFPcnNUS1pVa0d4LWJseVh3cEtVbkRTYzZiRzFTdHhTS2NscFlCSzQyU1VXWDZVOXdIZ3FVbENKejFF?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates AC Immune stock rating on trial data", "summary": "H.C. Wainwright reiterated a Buy rating and $12.00 price target on AC Immune SA (NASDAQ:ACIU) following interim 12-month data from its ABATE trial for prodromal Alzheimer\u2019s disease. The ACI-24 drug demonstrated safety and tolerability, with detected anti-Abeta antibody responses.", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-ac-immune-stock-rating-on-trial-data-93CH-4770234", "source_name": "Investing.com", "published_at": "2026-07-01T11:40:12", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AC Immune SA \u2013 DUS:IMR", "summary": "This article provides financial data for AC Immune SA (DUS:IMR) focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication and no trades had occurred. The content is primarily a data placeholder within the TradingView platf", "url": "https://www.tradingview.com/symbols/DUS-IMR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T02:38:57", "published_display": "01 Jul 2026 02:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides a brief financial overview for AC Immune SA (NASDAQ: ACIU), focusing on its forward price-to-sales ratio. It indicates the stock market for ACIU is currently closed with no trades. The content primarily shows the navigation and structure of a financial data ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T00:38:57", "published_display": "01 Jul 2026 00:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune Says Antibody Responses Detected in Phase 1b/2 Trial of ACI-24 in Alzheimer's Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ac-immune-says-antibody-responses-131927864.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:19:27+00:00", "published_display": "30 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda-backed AC Immune (NASDAQ: ACIU) reports ACI-24 Alzheimer\u2019s trial update", "summary": "AC Immune (NASDAQ: ACIU) announced interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial for ACI-24, an anti-amyloid beta active immunotherapy for prodromal Alzheimer's disease. The therapy was generally safe and well tolerated in 74 patients, with no A", "url": "https://www.stocktitan.net/sec-filings/ACIU/6-k-ac-immune-sa-current-report-foreign-issuer-27bbae36f4b4.html", "source_name": "Stock Titan", "published_at": "2026-06-30T13:10:17", "published_display": "30 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune\u2019s Alzheimer\u2019s vaccine shows antibody response in 74 patients", "summary": "AC Immune (NASDAQ: ACIU) reported positive 12-month interim data from its Phase 1b/2 ABATE trial of ACI-24 in 74 patients with prodromal Alzheimer's disease. The active immunotherapy was found to be generally safe and well-tolerated, inducing anti-Abeta antibody responses across ", "url": "https://www.stocktitan.net/news/ACIU/ac-immune-reports-interim-12-month-data-from-phase-1b-2-abate-trial-7bjx2o6zvkjs.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:10:17", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer\u2019s Disease", "summary": "AC Immune announced interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial, evaluating ACI-24 in patients with prodromal Alzheimer\u2019s disease. The ACI-24 anti-amyloid beta active immunotherapy was generally safe and well-tolerated, showing anti-Abeta anti", "url": "https://www.globenewswire.com/de/news-release/2026/06/30/3319524/0/en/AC-Immune-Reports-Interim-12-Month-Data-from-Phase-1b-2-ABATE-Trial-of-ACI-24-in-Prodromal-Alzheimer-s-Disease.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:10:17", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides financial information for AC Immune SA (ACIU) on the Nasdaq Stock Market, specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a section of a larger financial data service, showing market data and company details ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T00:41:20", "published_display": "30 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides information on the enterprise value to EBITDA forward for AC Immune SA (NASDAQ: ACIU). The content appears to be a financial data snippet from TradingView, offering a snapshot of this specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:40:17", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides a brief mention of AC Immune SA (NASDAQ: ACIU) and its \"Price to book forward\" metric. It appears to be a stub or a section from a larger financial data platform like TradingView, lacking detailed analysis or commentary. The content primarily lists navigatio", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:49", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "The article focuses on AC Immune SA (NASDAQ:ACIU) and its enterprise value to revenue forward metric. It appears to be an entry point to financial data on TradingView, providing an overview of the company's financials for investors and analysts interested in pharmaceutical stocks", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T01:10:33", "published_display": "28 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides financial data for AC Immune SA (NASDAQ: ACIU), specifically focusing on its enterprise value to EBIT forward. It indicates whether the market is currently open or closed and the trading status. The content primarily serves as a data point within a financial", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:51", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACIU Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an AC Immune SA (ACIU) stock forecast and price target for 2027 based on analyst opinions. It details the company's current stock performance, market capitalization, earnings, revenue, and other financial metrics. The article also includes frequently asked q", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T12:10:09", "published_display": "25 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune SA (ACIU) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "AC Immune SA (ACIU) has an earnings forecast score of 9.50, ranking 4th in its industry, with analysts assigning a \"Strong Buy\" rating and an average price target of $8.50. The company's expected revenue for the next quarter is $46.29M, and its previous quarter's EPS was -$0.18, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aciu/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T15:10:10", "published_display": "18 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune SA (ACIU) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for AC Immune SA (ACIU), indicating the company's valuation score is 8.02, ranking 174th in the Biotechnology & Medical Research industry. It highlights the current P/E ratio of -2.91, noting it is significantly below its recent high and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aciu/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T15:10:10", "published_display": "18 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) director receives new RSU and stock option grants", "summary": "AC Immune SA director Renee Aguiar-Lucander received equity compensation awards, specifically a restricted share unit grant of 16,568 common shares and options for 38,889 common shares, under the company's 2016 Stock Option and Incentive Plan. These awards were made on June 11, 2", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-b452e730ea0c.html", "source_name": "Stock Titan", "published_at": "2026-06-16T02:39:45", "published_display": "16 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) director receives restricted share units and options grant", "summary": "AC Immune SA director Roy Ervin Twyman was granted 16,568 restricted share units and options over 38,889 common shares on June 11, 2026, as part of his compensation under the company's 2016 Stock Option and Incentive Plan. The options have an exercise price of $2.62 per share, wi", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-5cb35280a714.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:39:21", "published_display": "15 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) grants RSUs and stock options to director Buetler", "summary": "AC Immune SA (ACIU) director Monika Buetler received equity awards comprising 17,751 restricted share units and options for 41,667 common shares. These grants, made on June 11, 2026, are part of her compensation under the company's 2016 Stock Option and Incentive Plan and increas", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-aa4f6ecabd9e.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:21", "published_display": "15 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] AC Immune SA Insider Trading Activity", "summary": "AC Immune SA director June Carl Howard reported new equity compensation grants on June 11, 2026. She received 16,568 common shares as a restricted share unit grant and share options for 38,889 common shares with an exercise price of $2.62 per share. These awards represent compens", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-9331640d3c79.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:21", "published_display": "15 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) interim CEO Martin Zuegel granted RSUs and stock options", "summary": "AC Immune SA's interim CEO, Martin Zuegel, received equity compensation awards on June 11, 2026, including 33,136 restricted share units and options for 77,778 common shares. The options have an exercise price of $2.6200 per share, will fully vest on June 10, 2027, and expire on ", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-021aaa919d27.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:21", "published_display": "15 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson\u2019s Disease", "summary": "AC Immune SA announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. This grant will support the extension of Part 1 of the ongoing Phase 2 VacSYn trial for ACI-7104, an anti-alpha-synuclein active immunotherapy for early Park", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ac-immune-receive-research-grant-110000107.html", "source_name": "Market source", "published_at": "2026-06-12T21:39:23", "published_display": "12 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS", "summary": "AC Immune SA announced new preliminary Phase 1 data demonstrating higher uptake of its TDP-43 PET tracer ACI-19626 in the brains of patients with amyotrophic lateral sclerosis (ALS) compared to healthy controls. The results, presented at the 2026 TDP43 Summit, indicate the tracer", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ac-immune-presents-phase-1-110000665.html", "source_name": "Market source", "published_at": "2026-06-12T00:09:39", "published_display": "12 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (NASDAQ: ACIU) AGM clears 2025 loss, extends capital band and boosts liquidity runway", "summary": "AC Immune shareholders approved all proposals at the June 2026 Annual General Meeting, including the 2025 financial statements and compensation report, despite reporting an IFRS loss of CHF 70.4 million on revenues of CHF 3.6 million, increasing accumulated losses to CHF 424.441 ", "url": "https://www.stocktitan.net/sec-filings/ACIU/6-k-ac-immune-sa-current-report-foreign-issuer-5fee340475ed.html", "source_name": "Stock Titan", "published_at": "2026-06-11T21:09:53", "published_display": "11 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune to Obtain $4 Million Research Grant From Foundation for Parkinson's Disease Therapy Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ac-immune-obtain-4-million-134337092.html", "source_name": "MT Newswires", "published_at": "2026-06-11T13:43:37+00:00", "published_display": "11 Jun 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNM2pDbHM3RlVXc2VxVUFHcklIYkN2Q1MyTlAzT2pXN3ctY3N1bkI3YlZjb0hIZXdXVnNKUm9OMVdCZVBtYUlhVXZkZmQ4SjU5ek9NU3dvSmJZZ0tpTUptemJCU0UzOTJGZ2x2MEkwTkFkaEJnUmJBdTRxaHNaUi1vQTF4eEljZHVMWkFkVTlzbk9KMHA5YnMw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQUnByTEt4a2JGV3FSM1lTVnJBeHdUQzJEUWJyY3RtV0c5SVMxeUZRMlNZRmgzNUNPNHhhdWhwOWNuOEF1T3VlSHlnTmRWajY0anFFSE9VZXZEMjZZcGRaTGctMVp0c052OTFRV1BlVURfRFhiUGY3bW03WVJBVGdpV2dvSWhCSkt5VlpMUWg3UTBXcE9Z?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AC Immune CEO exits after 23 years developing Alzheimer\u2019s drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQR29reE1wYzUxZGFiTFNvZmVpNVYtZEU1NXhMeFdrODAyempYX2ZtM1hxNXhSY01OZU1IYUtibkRGSmlRblMxLV9nVjdQM3drTmJfQjFabzVVSmM1dWxyZEIxRzNZRTE3Njd2dFFfS2RYZlN1bUFSUkNoNkRfaXlwRDFPdUsxUEZzRERSUVZ1Yzg5bXJabWpKdFBKLXRpV1BvZTVMWVVqZHNGY2gyRVAwUXRFTnBBeXZVd214ZGMwOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPclRDQlU1Rmp6YzAxdXllT3RLTUFLMXBFbTI1RXQ3WXllX0tIYm1XNFpFS2pqWnI4NG5FRWJIVXpvT0dIaGtNXzRhV3dFVTFpYnFRVzI3U0FoV01NYnlOTWFRY3Y2VXJPUXBnNE1IVXgxVGx4T3JIS05PaWQ3TkNWWW9vNEVKaEViYmI5a0g3SVBsbDVz?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNWjVmVlVSVUxWMWdTUE14WVVjTFd4aHRWVS1Sc2NGSjdpM2ZHaHpZb05Wc2xkWXFKSlN3RUx1bEk1Vi1aV3pwNUowMHF3bW5XT0R6VzR3VnUzdFF2S2NqZC1HQnBfNEdyZ2Nud25UbzNqYy0teFg0V2YxaGMzMEUxZ1ZmNmk2eGp3VGxyOXExSWtjeVBoNzdjazRMWjdER2pi?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune stock surges on amended Lilly collaboration deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZ3pLRmxxanRxWk1xdXI1R0JFdzBwUU5qVTlQS3dVNlpSaFYtNG93QVNCU3lGQkFsYUtpbHpqSFlfNG81aWtMeDYzVU5DMDZZVWpicUQ4elp4a3lwTVZVUlluYWlvdXh4LTJkNjMwcGM1dy1rQ290WmxaanBaVXM2el85bURuOFY4NEpuVVZwbVJUby1fcjJ0UVBCQmJ2SzZ4X3FwZGJ4MlJ0dy00UG9kdXZyZW1XMTBWeUNvUw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune rises after amending licensing deal with Lilly", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQdTN5QUl0UmdBZHFqZkF0SVpsclJFMzBLakN2ZTc5MU1JZUxyVTdXSmpISXVhWnIyRmhYNEdJbWI1dDNMcmZOZ0tEd1RQV1F3aEtSVzZrVi00elMzUER4Q3NfRWxiTFNhYlFFRGxrdUhyNVVJZDRybmNJbktqa0NwSG55OGY3QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AC IMMUNE SA (ACIU) Stock Price Today: $2.45", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE5uSmpFN1p5M294SXduSkhKbzZ5VnpqWThxbkdhWWNHT1dPNVpfZE9DcWotVlh2dVBpVDdDNW83OXJxQ0hsdlRxVTFtaGNDUWRSa1FIbE1paw?oc=5", "source_name": "Gotrade", "published_at": "2026-02-03T18:17:06+00:00", "published_display": "03 Feb 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune posts positive data for Parkinson\u2019s immunotherapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNdEVoT1JVY3JERzlub0dZTnpnN0NWUGJYMk9EaXI5QmdsamJKNk00UnI2ZHQ5RXdEVVNJTElrT2dzeFBWVUpsUEtwWEpjekY2dWJXZm1feWd2ell3cGZtejZvMC1qeEFfQXBWNWlaSTExMVh6dmtzS1F3UkxVVG5MaUZyR3VSTEtubWhMRnpWU0ZDZFVx?oc=5", "source_name": "BioPharma Dive", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACIU Stock Price and Chart \u2014 NASDAQ:ACIU", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE03T1FmbE9pZDJJUUVUaU5FYkdhQUd3WWx6a1JwWXY1V1Y5aWhHN1B2SXZ5Rmp6R1hvaWZPTDVlRXlyU052NWxiTGhTcWFsR243ejBZcEROaXJZeFp5?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T07:02:41+00:00", "published_display": "21 Jul 2017 07:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy AC Immune (ACIU)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1uc3MtY1Nmd1gyS3NueXJFamVIbjI2bFRvZF9UVzB1LVk1Z1BRQXRJUVFHRUVOYnRkSkI1bEI0OUxHS3g3bnZiRXl2S3AzNV8wLUV6bHRMMHVVdVVuTnE5Rm0tbFNqcmVoQmZSbA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-10-21T11:05:35+00:00", "published_display": "21 Oct 2016 11:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBGYmczendvWDMzVFZINzJQMFJyTFNqdTNVNy1nV05mZ05acHdZSGF6eGx3TVVkZHBGWXBWbUh6dWV5a3l1Um1HNDc5d3pYVjE3WkZJTS1UUVhtdw?oc=5", "source_name": "MarketBeat", "published_at": "2016-10-18T12:32:22+00:00", "published_display": "18 Oct 2016 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Swiss biotech AC Immune readies US IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOWFl3R2RhY2J1aEM3RlhTSF9PbWxPejNhS3VJN05POFhNYl9oYXRNbGVRLTVBRlNwOFBhdU5vZHdlc0pJbXFOOExxQ1RiVGtrOWhmNGVLQ2tLdUVYY1hrTmJHMG4zVXdUeU85SzdQb1BtZGxISEg5OU1IMnloVHd5cDJqWHF4eUhW?oc=5", "source_name": "BioPharma Dive", "published_at": "2016-06-02T07:00:00+00:00", "published_display": "02 Jun 2016 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC\u00ae 2026", "summary": "AC Immune SA announced it will present three times at the Alzheimer's Association International Conference\u00ae 2026, highlighting its Morphomer\u00ae-based small molecule approach for neurodegenerative diseases. The presentations will cover encouraging early human imaging data for a TDP-", "url": "https://finance.yahoo.com/healthcare/articles/ac-immune-showcase-neurodegenerative-disease-110000523.html", "source_name": "Market source", "published_at": "2026-07-08T13:14:12", "published_display": "08 Jul 2026 13:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune brings three neurodegeneration studies to AAIC 2026", "summary": "AC Immune (NASDAQ: ACIU) will present three pipeline studies at the Alzheimer's Association International Conference (AAIC) 2026, taking place from July 12-15 in London, UK. The presentations will cover a first-in-class TDP-43 PET tracer, a brain-penetrant NLRP3 inhibitor, and an", "url": "https://www.stocktitan.net/news/ACIU/ac-immune-to-showcase-neurodegenerative-disease-pipeline-with-three-663ci5zw1j5a.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:10:06", "published_display": "07 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune: Holding Into A Make-Or-Break H2 2026 Readout (NASDAQ:ACIU)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOc0loMmtzVXRJeFItM0FNWUpyRkJibnFsX040MlBuMkxleUpKSjh4QThPVGhSdHZ2VDVlVVo4elRNR0s0bkZzdld1dzY0bVFOcS1uOUdiZGFUeUJDTzFPcnNUS1pVa0d4LWJseVh3cEtVbkRTYzZiRzFTdHhTS2NscFlCSzQyU1VXWDZVOXdIZ3FVbENKejFF?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates AC Immune stock rating on trial data", "summary": "H.C. Wainwright reiterated a Buy rating and $12.00 price target on AC Immune SA (NASDAQ:ACIU) following interim 12-month data from its ABATE trial for prodromal Alzheimer\u2019s disease. The ACI-24 drug demonstrated safety and tolerability, with detected anti-Abeta antibody responses.", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-ac-immune-stock-rating-on-trial-data-93CH-4770234", "source_name": "Investing.com", "published_at": "2026-07-01T11:40:12", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AC Immune SA \u2013 DUS:IMR", "summary": "This article provides financial data for AC Immune SA (DUS:IMR) focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication and no trades had occurred. The content is primarily a data placeholder within the TradingView platf", "url": "https://www.tradingview.com/symbols/DUS-IMR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T02:38:57", "published_display": "01 Jul 2026 02:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides a brief financial overview for AC Immune SA (NASDAQ: ACIU), focusing on its forward price-to-sales ratio. It indicates the stock market for ACIU is currently closed with no trades. The content primarily shows the navigation and structure of a financial data ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T00:38:57", "published_display": "01 Jul 2026 00:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune Says Antibody Responses Detected in Phase 1b/2 Trial of ACI-24 in Alzheimer's Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ac-immune-says-antibody-responses-131927864.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:19:27+00:00", "published_display": "30 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda-backed AC Immune (NASDAQ: ACIU) reports ACI-24 Alzheimer\u2019s trial update", "summary": "AC Immune (NASDAQ: ACIU) announced interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial for ACI-24, an anti-amyloid beta active immunotherapy for prodromal Alzheimer's disease. The therapy was generally safe and well tolerated in 74 patients, with no A", "url": "https://www.stocktitan.net/sec-filings/ACIU/6-k-ac-immune-sa-current-report-foreign-issuer-27bbae36f4b4.html", "source_name": "Stock Titan", "published_at": "2026-06-30T13:10:17", "published_display": "30 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune\u2019s Alzheimer\u2019s vaccine shows antibody response in 74 patients", "summary": "AC Immune (NASDAQ: ACIU) reported positive 12-month interim data from its Phase 1b/2 ABATE trial of ACI-24 in 74 patients with prodromal Alzheimer's disease. The active immunotherapy was found to be generally safe and well-tolerated, inducing anti-Abeta antibody responses across ", "url": "https://www.stocktitan.net/news/ACIU/ac-immune-reports-interim-12-month-data-from-phase-1b-2-abate-trial-7bjx2o6zvkjs.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:10:17", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer\u2019s Disease", "summary": "AC Immune announced interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial, evaluating ACI-24 in patients with prodromal Alzheimer\u2019s disease. The ACI-24 anti-amyloid beta active immunotherapy was generally safe and well-tolerated, showing anti-Abeta anti", "url": "https://www.globenewswire.com/de/news-release/2026/06/30/3319524/0/en/AC-Immune-Reports-Interim-12-Month-Data-from-Phase-1b-2-ABATE-Trial-of-ACI-24-in-Prodromal-Alzheimer-s-Disease.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:10:17", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides financial information for AC Immune SA (ACIU) on the Nasdaq Stock Market, specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a section of a larger financial data service, showing market data and company details ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T00:41:20", "published_display": "30 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides information on the enterprise value to EBITDA forward for AC Immune SA (NASDAQ: ACIU). The content appears to be a financial data snippet from TradingView, offering a snapshot of this specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:40:17", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides a brief mention of AC Immune SA (NASDAQ: ACIU) and its \"Price to book forward\" metric. It appears to be a stub or a section from a larger financial data platform like TradingView, lacking detailed analysis or commentary. The content primarily lists navigatio", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:49", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "The article focuses on AC Immune SA (NASDAQ:ACIU) and its enterprise value to revenue forward metric. It appears to be an entry point to financial data on TradingView, providing an overview of the company's financials for investors and analysts interested in pharmaceutical stocks", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T01:10:33", "published_display": "28 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of AC Immune SA \u2013 NASDAQ:ACIU", "summary": "This article provides financial data for AC Immune SA (NASDAQ: ACIU), specifically focusing on its enterprise value to EBIT forward. It indicates whether the market is currently open or closed and the trading status. The content primarily serves as a data point within a financial", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:51", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACIU Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an AC Immune SA (ACIU) stock forecast and price target for 2027 based on analyst opinions. It details the company's current stock performance, market capitalization, earnings, revenue, and other financial metrics. The article also includes frequently asked q", "url": "https://www.tradingview.com/symbols/NASDAQ-ACIU/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T12:10:09", "published_display": "25 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune SA (ACIU) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "AC Immune SA (ACIU) has an earnings forecast score of 9.50, ranking 4th in its industry, with analysts assigning a \"Strong Buy\" rating and an average price target of $8.50. The company's expected revenue for the next quarter is $46.29M, and its previous quarter's EPS was -$0.18, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aciu/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T15:10:10", "published_display": "18 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune SA (ACIU) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for AC Immune SA (ACIU), indicating the company's valuation score is 8.02, ranking 174th in the Biotechnology & Medical Research industry. It highlights the current P/E ratio of -2.91, noting it is significantly below its recent high and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aciu/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T15:10:10", "published_display": "18 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) director receives new RSU and stock option grants", "summary": "AC Immune SA director Renee Aguiar-Lucander received equity compensation awards, specifically a restricted share unit grant of 16,568 common shares and options for 38,889 common shares, under the company's 2016 Stock Option and Incentive Plan. These awards were made on June 11, 2", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-b452e730ea0c.html", "source_name": "Stock Titan", "published_at": "2026-06-16T02:39:45", "published_display": "16 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) director receives restricted share units and options grant", "summary": "AC Immune SA director Roy Ervin Twyman was granted 16,568 restricted share units and options over 38,889 common shares on June 11, 2026, as part of his compensation under the company's 2016 Stock Option and Incentive Plan. The options have an exercise price of $2.62 per share, wi", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-5cb35280a714.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:39:21", "published_display": "15 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) grants RSUs and stock options to director Buetler", "summary": "AC Immune SA (ACIU) director Monika Buetler received equity awards comprising 17,751 restricted share units and options for 41,667 common shares. These grants, made on June 11, 2026, are part of her compensation under the company's 2016 Stock Option and Incentive Plan and increas", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-aa4f6ecabd9e.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:21", "published_display": "15 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] AC Immune SA Insider Trading Activity", "summary": "AC Immune SA director June Carl Howard reported new equity compensation grants on June 11, 2026. She received 16,568 common shares as a restricted share unit grant and share options for 38,889 common shares with an exercise price of $2.62 per share. These awards represent compens", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-9331640d3c79.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:21", "published_display": "15 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) interim CEO Martin Zuegel granted RSUs and stock options", "summary": "AC Immune SA's interim CEO, Martin Zuegel, received equity compensation awards on June 11, 2026, including 33,136 restricted share units and options for 77,778 common shares. The options have an exercise price of $2.6200 per share, will fully vest on June 10, 2027, and expire on ", "url": "https://www.stocktitan.net/sec-filings/ACIU/form-4-ac-immune-sa-insider-trading-activity-021aaa919d27.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:21", "published_display": "15 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson\u2019s Disease", "summary": "AC Immune SA announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. This grant will support the extension of Part 1 of the ongoing Phase 2 VacSYn trial for ACI-7104, an anti-alpha-synuclein active immunotherapy for early Park", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ac-immune-receive-research-grant-110000107.html", "source_name": "Market source", "published_at": "2026-06-12T21:39:23", "published_display": "12 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS", "summary": "AC Immune SA announced new preliminary Phase 1 data demonstrating higher uptake of its TDP-43 PET tracer ACI-19626 in the brains of patients with amyotrophic lateral sclerosis (ALS) compared to healthy controls. The results, presented at the 2026 TDP43 Summit, indicate the tracer", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ac-immune-presents-phase-1-110000665.html", "source_name": "Market source", "published_at": "2026-06-12T00:09:39", "published_display": "12 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (NASDAQ: ACIU) AGM clears 2025 loss, extends capital band and boosts liquidity runway", "summary": "AC Immune shareholders approved all proposals at the June 2026 Annual General Meeting, including the 2025 financial statements and compensation report, despite reporting an IFRS loss of CHF 70.4 million on revenues of CHF 3.6 million, increasing accumulated losses to CHF 424.441 ", "url": "https://www.stocktitan.net/sec-filings/ACIU/6-k-ac-immune-sa-current-report-foreign-issuer-5fee340475ed.html", "source_name": "Stock Titan", "published_at": "2026-06-11T21:09:53", "published_display": "11 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune to Obtain $4 Million Research Grant From Foundation for Parkinson's Disease Therapy Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ac-immune-obtain-4-million-134337092.html", "source_name": "MT Newswires", "published_at": "2026-06-11T13:43:37+00:00", "published_display": "11 Jun 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNM2pDbHM3RlVXc2VxVUFHcklIYkN2Q1MyTlAzT2pXN3ctY3N1bkI3YlZjb0hIZXdXVnNKUm9OMVdCZVBtYUlhVXZkZmQ4SjU5ek9NU3dvSmJZZ0tpTUptemJCU0UzOTJGZ2x2MEkwTkFkaEJnUmJBdTRxaHNaUi1vQTF4eEljZHVMWkFkVTlzbk9KMHA5YnMw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQUnByTEt4a2JGV3FSM1lTVnJBeHdUQzJEUWJyY3RtV0c5SVMxeUZRMlNZRmgzNUNPNHhhdWhwOWNuOEF1T3VlSHlnTmRWajY0anFFSE9VZXZEMjZZcGRaTGctMVp0c052OTFRV1BlVURfRFhiUGY3bW03WVJBVGdpV2dvSWhCSkt5VlpMUWg3UTBXcE9Z?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune CEO exits after 23 years developing Alzheimer\u2019s drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQR29reE1wYzUxZGFiTFNvZmVpNVYtZEU1NXhMeFdrODAyempYX2ZtM1hxNXhSY01OZU1IYUtibkRGSmlRblMxLV9nVjdQM3drTmJfQjFabzVVSmM1dWxyZEIxRzNZRTE3Njd2dFFfS2RYZlN1bUFSUkNoNkRfaXlwRDFPdUsxUEZzRERSUVZ1Yzg5bXJabWpKdFBKLXRpV1BvZTVMWVVqZHNGY2gyRVAwUXRFTnBBeXZVd214ZGMwOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPclRDQlU1Rmp6YzAxdXllT3RLTUFLMXBFbTI1RXQ3WXllX0tIYm1XNFpFS2pqWnI4NG5FRWJIVXpvT0dIaGtNXzRhV3dFVTFpYnFRVzI3U0FoV01NYnlOTWFRY3Y2VXJPUXBnNE1IVXgxVGx4T3JIS05PaWQ3TkNWWW9vNEVKaEViYmI5a0g3SVBsbDVz?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNWjVmVlVSVUxWMWdTUE14WVVjTFd4aHRWVS1Sc2NGSjdpM2ZHaHpZb05Wc2xkWXFKSlN3RUx1bEk1Vi1aV3pwNUowMHF3bW5XT0R6VzR3VnUzdFF2S2NqZC1HQnBfNEdyZ2Nud25UbzNqYy0teFg0V2YxaGMzMEUxZ1ZmNmk2eGp3VGxyOXExSWtjeVBoNzdjazRMWjdER2pi?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune stock surges on amended Lilly collaboration deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZ3pLRmxxanRxWk1xdXI1R0JFdzBwUU5qVTlQS3dVNlpSaFYtNG93QVNCU3lGQkFsYUtpbHpqSFlfNG81aWtMeDYzVU5DMDZZVWpicUQ4elp4a3lwTVZVUlluYWlvdXh4LTJkNjMwcGM1dy1rQ290WmxaanBaVXM2el85bURuOFY4NEpuVVZwbVJUby1fcjJ0UVBCQmJ2SzZ4X3FwZGJ4MlJ0dy00UG9kdXZyZW1XMTBWeUNvUw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune rises after amending licensing deal with Lilly", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQdTN5QUl0UmdBZHFqZkF0SVpsclJFMzBLakN2ZTc5MU1JZUxyVTdXSmpISXVhWnIyRmhYNEdJbWI1dDNMcmZOZ0tEd1RQV1F3aEtSVzZrVi00elMzUER4Q3NfRWxiTFNhYlFFRGxrdUhyNVVJZDRybmNJbktqa0NwSG55OGY3QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC IMMUNE SA (ACIU) Stock Price Today: $2.45", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE5uSmpFN1p5M294SXduSkhKbzZ5VnpqWThxbkdhWWNHT1dPNVpfZE9DcWotVlh2dVBpVDdDNW83OXJxQ0hsdlRxVTFtaGNDUWRSa1FIbE1paw?oc=5", "source_name": "Gotrade", "published_at": "2026-02-03T18:17:06+00:00", "published_display": "03 Feb 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune posts positive data for Parkinson\u2019s immunotherapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNdEVoT1JVY3JERzlub0dZTnpnN0NWUGJYMk9EaXI5QmdsamJKNk00UnI2ZHQ5RXdEVVNJTElrT2dzeFBWVUpsUEtwWEpjekY2dWJXZm1feWd2ell3cGZtejZvMC1qeEFfQXBWNWlaSTExMVh6dmtzS1F3UkxVVG5MaUZyR3VSTEtubWhMRnpWU0ZDZFVx?oc=5", "source_name": "BioPharma Dive", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACIU Stock Price and Chart \u2014 NASDAQ:ACIU", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE03T1FmbE9pZDJJUUVUaU5FYkdhQUd3WWx6a1JwWXY1V1Y5aWhHN1B2SXZ5Rmp6R1hvaWZPTDVlRXlyU052NWxiTGhTcWFsR243ejBZcEROaXJZeFp5?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T07:02:41+00:00", "published_display": "21 Jul 2017 07:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy AC Immune (ACIU)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1uc3MtY1Nmd1gyS3NueXJFamVIbjI2bFRvZF9UVzB1LVk1Z1BRQXRJUVFHRUVOYnRkSkI1bEI0OUxHS3g3bnZiRXl2S3AzNV8wLUV6bHRMMHVVdVVuTnE5Rm0tbFNqcmVoQmZSbA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-10-21T11:05:35+00:00", "published_display": "21 Oct 2016 11:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AC Immune (ACIU) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBGYmczendvWDMzVFZINzJQMFJyTFNqdTNVNy1nV05mZ05acHdZSGF6eGx3TVVkZHBGWXBWbUh6dWV5a3l1Um1HNDc5d3pYVjE3WkZJTS1UUVhtdw?oc=5", "source_name": "MarketBeat", "published_at": "2016-10-18T12:32:22+00:00", "published_display": "18 Oct 2016 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Swiss biotech AC Immune readies US IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOWFl3R2RhY2J1aEM3RlhTSF9PbWxPejNhS3VJN05POFhNYl9oYXRNbGVRLTVBRlNwOFBhdU5vZHdlc0pJbXFOOExxQ1RiVGtrOWhmNGVLQ2tLdUVYY1hrTmJHMG4zVXdUeU85SzdQb1BtZGxISEg5OU1IMnloVHd5cDJqWHF4eUhW?oc=5", "source_name": "BioPharma Dive", "published_at": "2016-06-02T07:00:00+00:00", "published_display": "02 Jun 2016 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 48, "sentiment_summary": {"positive": 14, "negative": 2, "neutral": 32, "score": 56, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 16.65, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 1.45, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 2.39, "latest_week": "2026-07-10", "one_week_move": -4.8, "four_week_move": 3.5, "twelve_week_move": -20.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.051771, "market_dynamics_buy_signal": false, "relative_strength": -27.855106, "fair_value_gap": -18.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.697, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.8% over one week, +3.5% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 10}, {"label": "Seeking Alpha", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.8% over one week, +3.5% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC\u00ae 2026"}], "updated_at": "2026-07-16T11:13:08.157561+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}